Saturday, 31 October 2026European Markets

European Corporate Finance

4 articles

Eutelsat launches €1.5bn senior notes offering as European refinancing activity accelerates

Eutelsat launches €1.5bn senior notes offering as European refinancing activity accelerates

Satellite operator Eutelsat is pursuing a €1.5 billion senior notes offering to refinance existing debt, part of a broader wave of corporate capital management activities across Europe and the US in early 2026. The refinancing trend reflects companies optimizing balance sheets amid favorable market conditions, with parallel initiatives including Duke Energy's $1 billion convertible notes offering.

ViaNews Editorial Team (Europe)•
European PE Firms Target 45-50% Margins as International Assets Hit 46% of Portfolio

European PE Firms Target 45-50% Margins as International Assets Hit 46% of Portfolio

Tikehau Capital set 2029 targets of €175-225m fee-related earnings and 45-50% core margins, up from 41% in 2025, as European private equity firms shift toward higher-margin strategies. The Paris-based manager's international assets now comprise 46% of total AuM versus 20% in 2016, reflecting broader sector expansion beyond home markets. Firms are maintaining selective deployment while positioning for improving European conditions.

ViaNews Editorial Team (Europe)•
European Private Equity Firms Target €60bn AUM as Tikehau Sets 76% Profit Growth Goal

European Private Equity Firms Target €60bn AUM as Tikehau Sets 76% Profit Growth Goal

Tikehau Capital projects fee-related earnings between €175m-€225m for 2026, up to 76% above 2025 levels and 50% beyond market expectations. European alternative asset managers are expanding internationally while maintaining selective deployment strategies with rejection rates exceeding 95%. The push coincides with favorable policy environments across European markets and growing demand for industrial real estate.

ViaNews Editorial Team (Europe)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com